About RAPHAS
RAPHAS was founded to turn lab innovations into practical products. They developed a novel drug delivery system using biodegradable microneedles for painless and efficient transdermal delivery.
RAPHAS’s proprietary technology has been successfully applied across various sectors, including cosmetics and pharmaceuticals. Notably, the company has made significant strides in the U.S. over-the-counter (OTC) pharmaceutical market. In August 2024, the company launched “ACROPASS ACNE CURE”, an acne treatment patch developed.
RAPHAS is expanding its horizons into medical applications, focusing on developing microneedle patches for vaccines, Allergy immunogenicity and pharmaceutical delivery systems. The company is committed to continuous research and development to create products that enhance health and well-being.
RAPHAS’s proprietary technology has been successfully applied across various sectors, including cosmetics and pharmaceuticals. Notably, the company has made significant strides in the U.S. over-the-counter (OTC) pharmaceutical market. In August 2024, the company launched “ACROPASS ACNE CURE”, an acne treatment patch developed.
RAPHAS is expanding its horizons into medical applications, focusing on developing microneedle patches for vaccines, Allergy immunogenicity and pharmaceutical delivery systems. The company is committed to continuous research and development to create products that enhance health and well-being.